IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지
DOI QR코드

DOI QR Code

Experimental Animal Models of Coronavirus Infections: Strengths and Limitations

  • Mark Anthony B. Casel (Department of Microbiology, College of Medicine and Medical Research Institute, Chungbuk National University) ;
  • Rare G. Rollon (Department of Microbiology, College of Medicine and Medical Research Institute, Chungbuk National University) ;
  • Young Ki Choi (Department of Microbiology, College of Medicine and Medical Research Institute, Chungbuk National University)
  • Received : 2021.02.08
  • Accepted : 2021.04.20
  • Published : 2021.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the emergence of SARS-CoV-2 in the human population in late 2019, it has spread on an unprecedented scale worldwide leading to the first coronavirus pandemic. SARS-CoV-2 infection results in a wide range of clinical manifestations from asymptomatic to fatal cases. Although intensive research has been undertaken to increase understanding of the complex biology of SARS-CoV-2 infection, the detailed mechanisms underpinning the severe pathogenesis and interactions between the virus and the host immune response are not well understood. Thus, the development of appropriate animal models that recapitulate human clinical manifestations and immune responses against SARS-CoV-2 is crucial. Although many animal models are currently available for the study of SARS-CoV-2 infection, each has distinct advantages and disadvantages, and some models show variable results between and within species. Thus, we aim to discuss the different animal models, including mice, hamsters, ferrets, and non-human primates, employed for SARS-CoV-2 infection studies and outline their individual strengths and limitations for use in studies aimed at increasing understanding of coronavirus pathogenesis. Moreover, a significant advantage of these animal models is that they can be tailored, providing unique options specific to the scientific goals of each researcher.

Keywords

Acknowledgement

This work was supported by the National Research Council of Science & Technology (NST) grant by the Korea government (MSIT) (No. CAP-20-01-KRIBB).

References

  1. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015;1282:1-23. https://doi.org/10.1007/978-1-4939-2438-7_1
  2. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019;17:181-192. https://doi.org/10.1038/s41579-018-0118-9
  3. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) [Internet]. Available at https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers#tab=tab_1 [accessed on 20 January 2021].
  4. World Health Organization. Who coronavirus disease (COVID-19) dashboard [Internet]. Available at https://covid19.who.int/ [accessed on 1 February 2021].
  5. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450-454. https://doi.org/10.1038/nature02145
  6. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11:875-879. https://doi.org/10.1038/nm1267
  7. Medina-Enriquez MM, Lopez-Leon S, Carlos-Escalante JA, Aponte-Torres Z, Cuapio A, Wegman-Ostrosky T. ACE2: the molecular doorway to SARS-CoV-2. Cell Biosci 2020;10:148.
  8. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002;532:107-110. https://doi.org/10.1016/S0014-5793(02)03640-2
  9. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020;63:457-460. https://doi.org/10.1007/s11427-020-1637-5
  10. Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005;309:1864-1868. https://doi.org/10.1126/science.1116480
  11. Zou J, Yin J, Fang L, Yang M, Wang T, Wu W, Bellucci MA, Zhang P. Computational prediction of mutational effects on SARS-CoV-2 binding by relative free energy calculations. J Chem Inf Model 2020;60:5794-5802. https://doi.org/10.1021/acs.jcim.0c00679
  12. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-273. https://doi.org/10.1038/s41586-020-2012-7
  13. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46:586-590. https://doi.org/10.1007/s00134-020-05985-9
  14. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631-637. https://doi.org/10.1002/path.1570
  15. Tartey S, Takeuchi O. Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells. Int Rev Immunol 2017;36:57-73. https://doi.org/10.1080/08830185.2016.1261318
  16. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-820. https://doi.org/10.1016/j.cell.2010.01.022
  17. Krieg AM. AIMing 2 defend against intracellular pathogens. Nat Immunol 2010;11:367-369. https://doi.org/10.1038/ni0510-367
  18. Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of immune response during SARS-CoV-2 infection: lessons from the past. Front Immunol 2020;11:1949.
  19. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016;14:523-534. https://doi.org/10.1038/nrmicro.2016.81
  20. Wathelet MG, Orr M, Frieman MB, Baric RS. Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol 2007;81:11620-11633. https://doi.org/10.1128/JVI.00702-07
  21. Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, Wang C, Wang Y, Li L, Ren L, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun 2020;11:3810.
  22. Zhao L, Li J, Cui X, Jia N, Wei J, Xia L, Wang H, Zhou Y, Wang Q, Liu X, et al. Distribution of Haemaphysalis longicornis and associated pathogens: analysis of pooled data from a China field survey and global published data. Lancet Planet Health 2020;4:e320-e329. https://doi.org/10.1016/S2542-5196(20)30145-5
  23. Devaraj SG, Wang N, Chen Z, Chen Z, Tseng M, Barretto N, Lin R, Peters CJ, Tseng CT, Baker SC, et al. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J Biol Chem 2007;282:32208-32221. https://doi.org/10.1074/jbc.M704870200
  24. Frieman M, Ratia K, Johnston RE, Mesecar AD, Baric RS. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-κB signaling. J Virol 2009;83:6689-6705. https://doi.org/10.1128/JVI.02220-08
  25. Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang PC. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect 2004;10:1062-1066. https://doi.org/10.1111/j.1469-0691.2004.01009.x
  26. Corman VM, Albarrak AM, Omrani AS, Albarrak MM, Farah ME, Almasri M, Muth D, Sieberg A, Meyer B, Assiri AM, et al. Viral shedding and antibody response in 37 patients with middle east respiratory syndrome coronavirus infection. Clin Infect Dis 2016;62:477-483.
  27. Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaill J, Pillet S, Grattard F, Gonzalo S, Verhoeven P, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol 2021;18:318-327. https://doi.org/10.1038/s41423-020-00588-2
  28. Henss L, Scholz T, von Rhein C, Wieters I, Borgans F, Eberhardt FJ, Zacharowski K, Ciesek S, Rohde G, Vehreschild M. Analysis of humoral immune responses in SARS-CoV-2 infected patients. J Infect Dis 2020;223:56-61. https://doi.org/10.1093/infdis/jiaa680
  29. Lau EH, Tsang OT, Hui DS, Kwan MY, Chan WH, Chiu SS, Ko RL, Chan KH, Cheng SM, Perera RA, et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun 2021;12:63.
  30. Luchsinger LL, Ransegnola BP, Jin DK, Muecksch F, Weisblum Y, Bao W, George PJ, Rodriguez M, Tricoche N, Schmidt F, et al. Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients. J Clin Microbiol 2020;58:e02005-20. https://doi.org/10.1128/JCM.02005-20
  31. Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, McGuire J, Cleary S, Furrie E, Greig N, et al. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. J Infect Dis 2021;223:389-398. https://doi.org/10.1093/infdis/jiaa659
  32. Wu F, Liu M, Wang A, Lu L, Wang Q, Gu C, Chen J, Wu Y, Xia S, Ling Y, et al. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in shanghai, china. JAMA Intern Med 2020;180:1356-1362. https://doi.org/10.1001/jamainternmed.2020.4616
  33. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, Damoraki G, Gkavogianni T, Adami ME, Katsaounou P, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 2020;27:992-1000.e3. https://doi.org/10.1016/j.chom.2020.04.009
  34. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
  35. Sit TH, Brackman CJ, Ip SM, Tam KW, Law PY, To EM, Yu VY, Sims LD, Tsang DN, Chu DK, et al. Infection of dogs with SARS-CoV-2. Nature 2020;586:776-778. https://doi.org/10.1038/s41586-020-2334-5
  36. Animal and Plant Health Inspection Service (US). USDA statement on the confirmation of COVID-19 in a tiger in New York [Internet]. Available at https://www.aphis.usda.gov/aphis/newsroom/news/sa_by_date/sa-2020/NY-zoo-covid-19 [accessed on 3 April 2021].
  37. Hobbs EC, Reid TJ. Animals and SARS-CoV-2: species susceptibility and viral transmission in experimental and natural conditions, and the potential implications for community transmission. Transbound Emerg Dis 2020. doi: 10.1111/tbed.13885.
  38. Oreshkova N, Molenaar RJ, Vreman S, Harders F, Oude Munnink BB, Hakze-van der Honing RW, Gerhards N, Tolsma P, Bouwstra R, Sikkema R, et al. SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. Euro Surveill 2020;25:2001005.
  39. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172:2731-2738. https://doi.org/10.4049/jimmunol.172.5.2731
  40. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;94:e00127-20.
  41. Yang XH, Deng W, Tong Z, Liu YX, Zhang LF, Zhu H, Gao H, Huang L, Liu YL, Ma CM, et al. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. Comp Med 2007;57:450-459.
  42. McCray PB Jr, Pewe L, Wohlford-Lenane C, Hickey M, Manzel L, Shi L, Netland J, Jia HP, Halabi C, Sigmund CD, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol 2007;81:813-821. https://doi.org/10.1128/JVI.02012-06
  43. Tseng CT, Huang C, Newman P, Wang N, Narayanan K, Watts DM, Makino S, Packard MM, Zaki SR, Chan TS, et al. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. J Virol 2007;81:1162-1173. https://doi.org/10.1128/JVI.01702-06
  44. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol 2008;82:7264-7275. https://doi.org/10.1128/JVI.00737-08
  45. Yoshikawa N, Yoshikawa T, Hill T, Huang C, Watts DM, Makino S, Milligan G, Chan T, Peters CJ, Tseng CT. Differential virological and immunological outcome of severe acute respiratory syndrome coronavirus infection in susceptible and resistant transgenic mice expressing human angiotensin-converting enzyme 2. J Virol 2009;83:5451-5465. https://doi.org/10.1128/JVI.02272-08
  46. Menachery VD, Yount BL Jr, Sims AC, Debbink K, Agnihothram SS, Gralinski LE, Graham RL, Scobey T, Plante JA, Royal SR, et al. SARS-like WIV1-CoV poised for human emergence. Proc Natl Acad Sci U S A 2016;113:3048-3053. https://doi.org/10.1073/pnas.1517719113
  47. Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, Wei Q, Yu P, Xu Y, Qi F, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 2020;583:830-833. https://doi.org/10.1038/s41586-020-2312-y
  48. Jiang RD, Liu MQ, Chen Y, Shan C, Zhou YW, Shen XR, Li Q, Zhang L, Zhu Y, Si HR, et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell 2020;182:50-58.e8. https://doi.org/10.1016/j.cell.2020.05.027
  49. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, Collange O, Boulay C, Fafi-Kremer S, Ohana M, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020;382:2268-2270. https://doi.org/10.1056/NEJMc2008597
  50. Gu H, Chen Q, Yang G, He L, Fan H, Deng YQ, Wang Y, Teng Y, Zhao Z, Cui Y, et al. Rapid adaptation of SARS-CoV-2 in BALB/c mice: novel mouse model for vaccine efficacy. bioRxiv 2020. doi: 10.1101/2020.05.02.073411.
  51. Dinnon KH 3rd, Leist SR, Schafer A, Edwards CE, Martinez DR, Montgomery SA, West A, Yount BL Jr, Hou YJ, Adams LE, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 2020;586:560-566. https://doi.org/10.1038/s41586-020-2708-8
  52. Yun SM, Park SJ, Kim YI, Park SW, Yu MA, Kwon HI, Kim EH, Yu KM, Jeong HW, Ryou J, et al. Genetic and pathogenic diversity of severe fever with thrombocytopenia syndrome virus (SFTSV) in South Korea. JCI Insight 2020;5:e129531.
  53. Hassan AO, Case JB, Winkler ES, Thackray LB, Kafai NM, Bailey AL, McCune BT, Fox JM, Chen RE, Alsoussi WB, et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell 2020;182:744-753.e4. https://doi.org/10.1016/j.cell.2020.06.011
  54. Israelow B, Song E, Mao T, Lu P, Meir A, Liu F, Alfajaro MM, Wei J, Dong H, Homer RJ, et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J Exp Med 2020;217:e20201241.
  55. Rathnasinghe R, Strohmeier S, Amanat F, Gillespie VL, Krammer F, Garcia-Sastre A, Coughlan L, Schotsaert M, Uccellini MB. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect 2020;9:2433-2445. https://doi.org/10.1080/22221751.2020.1838955
  56. Takao K, Miyakawa T. Genomic responses in mouse models greatly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2015;112:1167-1172. https://doi.org/10.1073/pnas.1401965111
  57. Shay T, Jojic V, Zuk O, Rothamel K, Puyraimond-Zemmour D, Feng T, Wakamatsu E, Benoist C, Koller D, Regev A, et al. Conservation and divergence in the transcriptional programs of the human and mouse immune systems. Proc Natl Acad Sci U S A 2013;110:2946-2951. https://doi.org/10.1073/pnas.1222738110
  58. Ernst W. Humanized mice in infectious diseases. Comp Immunol Microbiol Infect Dis 2016;49:29-38. https://doi.org/10.1016/j.cimid.2016.08.006
  59. Brumeanu TD, Vir P, Shashikumar S, Karim AF, Kar S, Chung KK, Pratt KP, Casares S. A Human-Immune-System mouse model for COVID-19 research (DRAGA mouse: HLA-A2.HLA-DR4.Rag1KO.IL-2Rγc KO.NOD). bioRxiv 2021. doi: 10.1101/2020.08.19.251249.
  60. Tu W, Zheng J. Application of humanized mice in immunological research. Methods Mol Biol 2016;1371:157-176. https://doi.org/10.1007/978-1-4939-3139-2_10
  61. Miao J, Chard LS, Wang Z, Wang Y. Syrian hamster as an animal model for the study on infectious diseases. Front Immunol 2019;10:2329.
  62. Chan JF, Zhang AJ, Yuan S, Poon VK, Chan CC, Lee AC, Chan WM, Fan Z, Tsoi HW, Wen L, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis 2020;71:2428-2446. https://doi.org/10.1093/cid/ciaa644
  63. Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, Watanabe T, Ujie M, Takahashi K, Ito M, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A 2020;117:16587-16595. https://doi.org/10.1073/pnas.2009799117
  64. Sia SF, Yan LM, Chin AW, Fung K, Choy KT, Wong AY, Kaewpreedee P, Perera RA, Poon LL, Nicholls JM, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 2020;583:834-838. https://doi.org/10.1038/s41586-020-2342-5
  65. Boudewijns R, Thibaut HJ, Kaptein SJ, Li R, Vergote V, Seldeslachts L, De Keyzer C, Bervoets L, Sharma S, Van Weyenbergh J, et al. STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters. bioRxiv 2020. doi: 10.1101/2020.04.23.056838.
  66. Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y, Liu X, Xie L, Li J, Ye J, et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov 2020;6:31.
  67. Zhang D, Guo R, Lei L, Liu H, Wang Y, Wang Y, Qian H, Dai T, Zhang T, Lai Y, et al. Frontline science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. J Leukoc Biol 2021;109:13-22. https://doi.org/10.1002/JLB.4HI0720-470R
  68. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-1518. https://doi.org/10.1056/NEJMoa1215134
  69. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJHLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
  70. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med 2020;217:e20200678.
  71. Brocato RL, Principe LM, Kim RK, Zeng X, Williams JA, Liu Y, Li R, Smith JM, Golden JW, Gangemi D, et al. Disruption of adaptive immunity enhances disease in sars-cov-2-infected syrian hamsters. J Virol 2020;94:e01683-20.
  72. Osterrieder N, Bertzbach LD, Dietert K, Abdelgawad A, Vladimirova D, Kunec D, Hoffmann D, Beer M, Gruber AD, Trimpert J. Age-dependent progression of SARS-CoV-2 infection in syrian hamsters. Viruses 2020;12:779.
  73. Trimpert J, Vladimirova D, Dietert K, Abdelgawad A, Kunec D, Dokel S, Voss A, Gruber AD, Bertzbach LD, Osterrieder N. The roborovski dwarf hamster is a highly susceptible model for a rapid and fatal course of Sars-CoV-2 infection. Cell Reports 2020;33:108488.
  74. Cleary SJ, Pitchford SC, Amison RT, Carrington R, Robaina Cabrera CL, Magnen M, Looney MR, Gray E, Page CP. Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology. Br J Pharmacol 2020;177:4851-4865. https://doi.org/10.1111/bph.15143
  75. Chu YK, Ali GD, Jia F, Li Q, Kelvin D, Couch RC, Harrod KS, Hutt JA, Cameron C, Weiss SR, et al. The SARS-CoV ferret model in an infection-challenge study. Virology 2008;374:151-163. https://doi.org/10.1016/j.virol.2007.12.032
  76. Zhang Q, Shi J, Deng G, Guo J, Zeng X, He X, Kong H, Gu C, Li X, Liu J, et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 2013;341:410-414. https://doi.org/10.1126/science.1240532
  77. Stittelaar KJ, de Waal L, van Amerongen G, Veldhuis Kroeze EJ, Fraaij PL, van Baalen CA, van Kampen JJ, van der Vries E, Osterhaus AD, de Swart RL. Ferrets as a novel animal model for studying human respiratory syncytial virus infections in immunocompetent and immunocompromised hosts. Viruses 2016;8:168.
  78. Kim YI, Kim SG, Kim SM, Kim EH, Park SJ, Yu KM, Chang JH, Kim EJ, Lee S, Casel MAB, et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe 2020;27:704-709.e2. https://doi.org/10.1016/j.chom.2020.03.023
  79. Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, Liu R, He X, Shuai L, Sun Z, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 2020;368:1016-1020. https://doi.org/10.1126/science.abb7015
  80. Johnson-Delaney CA, Orosz SE. Ferret respiratory system: clinical anatomy, physiology, and disease. Vet Clin North Am Exot Anim Pract 2011;14:357-367, vii. https://doi.org/10.1016/j.cvex.2011.03.001
  81. Enkirch T, von Messling V. Ferret models of viral pathogenesis. Virology 2015;479-480:259-270. https://doi.org/10.1016/j.virol.2015.03.017
  82. Kim YI, Kim SM, Park SJ, Kim EH, Yu KM, Chang JH, Kim EJ, Casel MAB, Rollon R, Jang SG, et al. Critical role of neutralizing antibody for sars-cov-2 reinfection and transmission. Emerg Microbes Infect 2021;10:152-160. https://doi.org/10.1080/22221751.2021.1872352
  83. GISAID. Pandemic coronavirus causing COVID-19 [Internet]. Available at https://www.epicov.org/epi3/frontend#264948 [accessed on 14January 2021].
  84. Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol 2018;18:35-45. https://doi.org/10.1038/nri.2017.76
  85. Stubbington MJ, Rozenblatt-Rosen O, Regev A, Teichmann SA. Single-cell transcriptomics to explore the immune system in health and disease. Science 2017;358:58-63. https://doi.org/10.1126/science.aan6828
  86. Zhang JY, Wang XM, Xing X, Xu Z, Zhang C, Song JW, Fan X, Xia P, Fu JL, Wang SY, et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat Immunol 2020;21:1107-1118. https://doi.org/10.1038/s41590-020-0762-x
  87. Lee JS, Koh JY, Yi K, Kim YI, Park SJ, Kim EH, Kim SM, Park SH, Ju YS, Choi YK, et al. Single-cell transcriptome of bronchoalveolar lavage fluid reveals dynamic change of macrophages during SARS-CoV-2 infection in ferrets. bioRxiv 2020. doi: 10.1101/2020.11.18.388280.
  88. Yu P, Qi F, Xu Y, Li F, Liu P, Liu J, Bao L, Deng W, Gao H, Xiang Z, et al. Age-related rhesus macaque models of COVID-19. Animal Model Exp Med 2020;3:93-97. https://doi.org/10.1002/ame2.12108
  89. Singh DK, Singh B, Ganatra SR, Gazi M, Cole J, Thippeshappa R, Alfson KJ, Clemmons E, Gonzalez O, Escobedo R, et al. Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets. Nat Microbiol 2021;6:73-86. https://doi.org/10.1038/s41564-020-00841-4
  90. Lu S, Zhao Y, Yu W, Yang Y, Gao J, Wang J, Kuang D, Yang M, Yang J, Ma C, et al. Comparison of nonhuman primates identified the suitable model for COVID-19. Signal Transduct Target Ther 2020;5:157.
  91. Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, Lv Q, Liu J, Yu P, Xu Y, et al. Lack of reinfection in rhesus macaques infected with SARS-CoV-2. bioRxiv 2020. doi: 10.1101/2020.03.13.990226.
  92. Rockx B, Kuiken T, Herfst S, Bestebroer T, Lamers MM, Oude Munnink BB, de Meulder D, van Amerongen G, van den Brand J, Okba NM, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 2020;368:1012-1015. https://doi.org/10.1126/science.abb7314
  93. Woolsey C, Borisevich V, Prasad AN, Agans KN, Deer DJ, Dobias NS, Heymann JC, Foster SL, Levine CB, Medina L, et al. Establishment of an African green monkey model for COVID-19 and protection against re-infection. Nat Immunol 2021;22:86-98. https://doi.org/10.1038/s41590-020-00835-8
  94. Liu R, Wang Y, Li J, Han H, Xia Z, Liu F, Wu K, Yang L, Liu X, Zhu C. Decreased T cell populations contribute to the increased severity of COVID-19. Clin Chim Acta 2020;508:110-114. https://doi.org/10.1016/j.cca.2020.05.019
  95. Wilk AJ, Rustagi A, Zhao NQ, Roque J, Martinez-Colon GJ, McKechnie JL, Ivison GT, Ranganath T, Vergara R, Hollis T, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med 2020;26:1070-1076. https://doi.org/10.1038/s41591-020-0944-y
  96. Munster VJ, Feldmann F, Williamson BN, van Doremalen N, Perez-Perez L, Schulz J, Meade-White K, Okumura A, Callison J, Brumbaugh B, et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature 2020;585:268-272. https://doi.org/10.1038/s41586-020-2324-7
  97. Scientific Committee on Health, Environmental and Emerging Risks (SCHEER). The need for non-human primates in biomedical research, production and testing of products and devices. Brussels: European Union; 2009.
  98. Maiese A, Manetti AC, La Russa R, Di Paolo M, Turillazzi E, Frati P, Fineschi V. Autopsy findings in COVID-19-related deaths: a literature review. Forensic Sci Med Pathol 2020;1-18.
  99. Mohanty SK, Satapathy A, Naidu MM, Mukhopadhyay S, Sharma S, Barton LM, Stroberg E, Duval EJ, Pradhan D, Tzankov A, et al. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19) - anatomic pathology perspective on current knowledge. Diagn Pathol 2020;15:103.